Fremanezumab for the Preventive Treatment of Chronic Migraine

Fremanezumab is a monoclonal antibody aimed at preventing chronic migraines. This study compared its effectiveness to placebo in a phase 3 trial. Patients with chronic migraines received one of three treatments. They received fremanezumab either quarterly, monthly, or a matching placebo. A total of 1130 patients participated in this study. The average number of headache days per month was measured. Patients receiving fremanezumab quarterly had a reduction of 4.3 days. Those on monthly fremanezumab experienced a 4.6-day reduction. Placebo group patients saw a reduction of only 2.5 days. Also, 38% of quarterly and 41% of monthly patients had at least a 50% reduction in headache days. In comparison, only 18% of placebo patients achieved this. Injection-site reactions occurred frequently. While fremanezumab reduces headache frequency, long-term safety studies are needed. Clinical relevance: This research supports fremanezumab as an effective preventive treatment for chronic migraine patients.